FNCH - Finch Therapeutics Group, Inc. Stock Price, Fair Value and News

2.00USD+0.08 (+4.17%)Delayed as of 17 May 2024, 12:41 pm ET

Market Summary

USD2.00+0.08

Delayedas of 17 May 2024, 12:41 pm

4.17%

FNCH Stock Price

View Fullscreen

FNCH RSI Chart

FNCH Valuation

Market Cap

3.1M

Price/Earnings (Trailing)

-0.19

Price/Sales (Trailing)

28.81

EV/EBITDA

1.17

Price/Free Cashflow

-0.14

FNCH Price/Sales (Trailing)

FNCH Profitability

EBT Margin

-14473.83%

Return on Equity

-85.53%

Return on Assets

-32.51%

Free Cashflow Yield

-728.89%

FNCH Fundamentals

FNCH Revenue

Revenue (TTM)

107.0K

Rev. Growth (Yr)

184.06%

Rev. Growth (Qtr)

-6.67%

FNCH Earnings

Earnings (TTM)

-16.3M

Earnings Growth (Yr)

93.78%

Earnings Growth (Qtr)

-27.46%

Breaking Down FNCH Revenue

52 Week Range

2.04

(Low)(High)

Last 7 days

-3.9%

Last 30 days

-37.1%

Last 90 days

-22%

Trailing 12 Months

-80.9%

How does FNCH drawdown profile look like?

FNCH Financial Health

Current Ratio

6.05

FNCH Investor Care

Shares Dilution (1Y)

0.06%

Diluted EPS (TTM)

-9.62

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	932.0K	991.0K	1.2M	107.0K
2022	14.1M	9.7M	5.3M	861.0K
2021	9.5M	10.0M	19.5M	18.5M
2020	0	0	0	7.7M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Finch Therapeutics Group, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 28, 2024	smisek jeffery a	sold	-17,069	2.57	-6,642	-
Mar 28, 2024	smisek jeffery a	sold	-4,176	2.61	-1,600	-
Nov 22, 2023	smisek jeffery a	sold	-5,350	3.64	-1,470	-
Jun 09, 2023	graf susan e	bought	1,352	0.27	5,010	-
Feb 21, 2023	blaustein marc	sold	-1,755	0.38	-4,619	chief operating officer
Oct 21, 2022	blaustein marc	sold	-5,054	1.39	-3,636	chief operating officer
Oct 21, 2022	vittiglio joseph	sold	-5,054	1.39	-3,636	chief business & legal officer
Jun 13, 2022	vittiglio joseph	acquired	-	-	35,000	chief business & legal officer
Jun 13, 2022	blaustein marc	acquired	-	-	35,000	chief operating officer
Dec 20, 2021	haft nicholas	bought	649,993	10.18	63,850	-

Which funds bought or sold FNCH recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	MORGAN STANLEY	added	26.83	-38.00	406	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-43.00	-	-%
May 15, 2024	Ikarian Capital, LLC	unchanged	-	-6,755	18,126	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	58.53	1,344	10,824	-%
May 15, 2024	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	sold off	-100	-509	-	-%
May 15, 2024	Royal Bank of Canada	unchanged	-	-	-	-%
May 14, 2024	Bleichroeder LP	unchanged	-	-980	2,525	-%
May 14, 2024	BAUPOST GROUP LLC/MA	sold off	-100	-243,000	-	-%
May 13, 2024	LAKE STREET ADVISORS GROUP, LLC	new	-	55,670	55,670	-%
May 13, 2024	UBS Group AG	added	5,400	279	286	-%

Are Funds Buying or Selling FNCH?

Are funds buying FNCH calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own FNCH

No. of Funds

Unveiling Finch Therapeutics Group, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Dec 13, 2023	ugwumba chidozie	9.99%	160,366	SC 13G
Feb 14, 2022	walton thomas layton	0%	0	SC 13G
Feb 14, 2022	ugwumba chidozie	7.37%	3,500,000	SC 13G

Recent SEC filings of Finch Therapeutics Group, Inc.

View All Filings

Date Filed	Form Type	Document
May 10, 2024	10-Q	Quarterly Report
Apr 26, 2024	10-K/A	Annual Report
Apr 03, 2024	8-K	Current Report
Mar 29, 2024	4	Insider Trading
Mar 28, 2024	144	Notice of Insider Sale Intent
Mar 25, 2024	10-K	Annual Report
Feb 23, 2024	8-K	Current Report

Peers (Alternatives to Finch Therapeutics Group, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	27.86%	5.69%	-8.52	7.43	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	3.08%	-21.73%	-57.61	9.55	75.20%	68.82%
BMRN	14.6B	2.5B	-15.33%	-16.61%	71.11	5.91	13.74%	186.89%
INCY	12.8B	3.8B	6.86%	-11.90%	17.13	3.39	8.58%	129.81%
MID-CAP
BBIO	5.8B	107.9M	23.06%	120.60%	-10.63	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.99%	-52.96%	-12.22	9.73	394.93%	39.61%
AXSM	3.7B	251.0M	12.53%	-1.35%	-12.4	14.64	73.58%	-86.73%
ARWR	3.1B	240.7M	5.66%	-32.59%	-6.6	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.11%	-34.57%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
NVAX	2.0B	996.6M	260.65%	85.68%	-5.07	2.03	-26.66%	65.49%
CPRX	1.9B	411.3M	5.34%	30.65%	29.69	4.7	60.38%	-34.49%
CRBP	489.5M	881.7K	11.38%	343.80%	-14.5	481.06	-77.61%	33.36%
INO	330.9M	4.9M	32.47%	47.80%	-2.65	67.99	-54.97%	48.23%
IBIO	15.7M	2.1M	-6.67%	89.09%	-0.68	7.61	-13.45%	69.54%

Finch Therapeutics Group, Inc. News

Latest updates

Finch Therapeutics Group, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Revenue	-	-	-	392,000	420,000	425,000	8,000	138,000	361,000	583,500	806,000	11,343,000	2,830,000	3,553,000	1,807,000	1,771,000	2,349,000	1,792,000
Operating Expenses	43.6%	5,198,000	3,620,000	3,781,000	9,881,000	67,482,000	27,760,000	40,770,000	22,990,000	24,934,000	19,868,000	21,276,000	19,846,000	17,527,000	14,939,000	11,852,000	10,709,000	9,655,000
S&GA Expenses	-100.0%	-	4,681,000	3,735,000	8,877,000	9,617,000	9,040,000	9,584,000	8,164,000	9,404,000	5,065,000	5,739,000	5,882,000	4,552,000	6,372,000	2,807,000	2,574,000	2,258,000
R&D Expenses	100.0%	-	-796,000	-	203,000	8,588,000	11,551,000	11,859,000	13,923,000	15,530,000	14,803,000	15,537,000	13,964,000	12,975,000	8,567,000	9,045,000	8,135,000	7,397,000
EBITDA Margin	80.5%	-141	-722	-80.28	-137	-162	-125	-19.23	-7.44	-4.64	-3.01	-2.58	-5.11	-4.68	-4.99	-	-	-
Interest Expenses	-	-	-	-	-	202,000	334,000	334,000	71,000	2,000	2,000	2,000	2,000	3,000	3,000	4,000	3,000	1,000
Income Taxes	-	-	-	-	-	-3,461,000	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-72.7%	-3,876,000	-2,245,000	-2,416,000	-6,950,000	-67,400,000	-27,008,000	-40,371,000	-22,700,000	-24,567,000	-19,055,000	-9,955,000	-15,169,000	-13,981,000	-13,091,000	-10,090,000	-8,259,000	-7,901,000
EBT Margin	80.4%	-144	-738	-83.35	-143	-168	-133	-20.21	-7.87	-4.87	-3.14	-2.67	-5.25	-4.79	-5.10	-	-	-
Net Income	-27.5%	-3,876,000	-3,041,000	-2,416,000	-6,950,000	-62,347,000	-27,008,000	-40,371,000	-22,700,000	-24,567,000	-19,055,000	-9,955,000	-15,169,000	-13,981,000	-13,091,000	-10,090,000	-8,259,000	-7,901,000
Net Income Margin	78.2%	-152	-698	-79.29	-137	-163	-133	-20.21	-7.87	-4.87	-3.14	-2.67	-5.25	-4.79	-5.10	-	-	-
Free Cashflow	-18.1%	-4,362,000	-3,692,000	-5,261,000	-9,157,000	-13,395,000	-14,323,000	-19,422,000	-16,733,000	-26,555,000	-15,789,000	-16,713,000	-26,566,000	-24,048,000	-10,499,000	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet														(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	-9.5%	50.00	55.00	59.00	67.00	79.00	163	188	228	205	225	233	250	266	165
Current Assets	-18.1%	21.00	26.00	30.00	36.00	43.00	75.00	91.00	111	123	143	156	177	198	106
Cash Equivalents	-17.2%	21.00	25.00	29.00	34.00	42.00	71.00	85.00	105	107	133	149	168	193	100
Net PPE	-7.2%	1.00	1.00	1.00	1.00	1.00	16.00	17.00	18.00	19.00	20.00	20.00	18.00	16.00	7.00
Goodwill	-	-	-	-	-	-	-	-	18.00	18.00	18.00	18.00	18.00	18.00	18.00
Liabilities	-4.4%	31.00	32.00	34.00	39.00	46.00	67.00	67.00	69.00	25.00	23.00	13.00	22.00	26.00	28.00
Current Liabilities	-14.3%	3.00	4.00	5.00	10.00	13.00	15.00	14.00	15.00	17.00	15.00	9.00	10.00	12.00	11.00
Long Term Debt	-	-	-	-	-	-	15.00	15.00	15.00	-	-	-	-	2.00	2.00
LT Debt, Non Current	-	-	-	-	-	-	15.00	15.00	15.00	-	-	-	-	2.00	2.00
Shareholder's Equity	-16.8%	19.00	23.00	26.00	28.00	35.00	96.00	121	159	180	202	220	228	239	-
Retained Earnings	-1.1%	-354	-350	-347	-344	-339	-275	-248	-208	-185	-160	-141	-131	-116	-102
Additional Paid-In Capital	0.0%	373	373	373	373	372	371	369	367	365	363	362	360	356	7.00
Shares Outstanding	0%	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	2.00	0.00	0.00
Float	-	-	-	-	9.00	-	-	-	76.00	-	-	-	355	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Cashflow From Operations	-17.7%	-4,362	-3,706	-5,261	-9,157	-13,381	-14,272	-19,094	-15,839	-25,646	-13,787	-14,349	-23,783	-15,214	-10,282	-6,914	-8,162	-5,971
Share Based Compensation	-75.4%	28.00	114	335	300	1,180	1,793	2,101	1,830	2,120	1,406	1,515	905	335	2,876	57.00	88.00	78.00
Cashflow From Investing	-100.0%	-	51.00	20.00	1,270	-14.00	-51.00	-328	-894	-909	-2,002	-2,364	-2,731	-8,824	-2,146	-217	-198	-72.00
Cashflow From Financing	-	-	-	-	4.00	-16,159	52.00	41.00	14,775	5.00	70.00	45.00	1,628	117,367	-229	89,905	1,803	-4.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

FNCH Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Total revenue	$ 0	$ 107
Operating Expenses:
Research and development	0	6,996
General and administrative	5,164	9,617
Impairment of in-process research and development	0	32,900
Impairment of long-lived assets	0	13,141
Restructuring charges	34	3,236
Total operating expenses	5,198	65,890
Net loss from operations	(5,198)	(65,783)
Other Income (Expense), Net:
Interest income (expense), net	280	425
Loss on loan extinguishment	0	(1,366)
Loss on sale and disposal of fixed assets, net	0	(137)
Sublease and other income	1,042	1,053
Total other income (expense), net	1,322	(25)
Loss before income taxes	(3,876)	(65,808)
Income tax benefit	0	3,461
Net loss	$ (3,876)	$ (62,347)
Net loss per share attributable to common stockholders, basic	$ (2.41)	$ (39.19)
Net loss per share attributable to common stockholders, diluted	$ (2.41)	$ (39.19)
Weighted-average common stock outstanding, basic	1,605,763	1,602,852
Weighted-average common stock outstanding, diluted	1,605,763	1,602,852

FNCH Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current Assets:
Cash and cash equivalents	$ 20,762	$ 25,124
Prepaid expenses and other current assets	413	723
Total current assets	21,175	25,847
Property and equipment, net	551	594
Operating right-of-use assets	26,018	26,584
Restricted cash, non-current	2,348	2,348
Total Assets	50,092	55,373
Current Liabilities:
Accounts payable	47	141
Accrued expenses and other current liabilities	1,444	2,220
Operating lease liabilities, current	2,008	1,723
Total current liabilities	3,499	4,084
Operating lease liabilities, non-current	27,555	28,403
Total liabilities	31,054	32,487
Commitments and Contingencies (Note 8)
Preferred stock (undesignated), $0.001 par value; 10,000,000 shares authorized and no shares issued and outstanding as of March 31, 2024 and December 31, 2023	0	0
Stockholders' Equity:
Common stock, $0.001 par value; 200,000,000 shares authorized and 1,605,763 shares issued and outstanding as of March 31, 2024 and December 31, 2023	2	2
Additional paid-in capital	373,307	373,279
Accumulated deficit	(354,271)	(350,395)
Total stockholders' equity	19,038	22,886
Total Liabilities and Stockholders' Equity	$ 50,092	$ 55,373

About Finch Therapeutics Group, Inc.

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524, FIN-525, and other microbiome product candidates for inflammatory bowel disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.

WEBSITE	finchtherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	18

Finch Therapeutics Group, Inc. Frequently Asked Questions

What is the ticker symbol for Finch Therapeutics Group, Inc.? What does FNCH stand for in stocks?

FNCH is the stock ticker symbol of Finch Therapeutics Group, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Finch Therapeutics Group, Inc. (FNCH)?

As of Thu May 16 2024, market cap of Finch Therapeutics Group, Inc. is 3.08 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of FNCH stock?

You can check FNCH's fair value in chart for subscribers.

What is the fair value of FNCH stock?

You can check FNCH's fair value in chart for subscribers. The fair value of Finch Therapeutics Group, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Finch Therapeutics Group, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for FNCH so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Finch Therapeutics Group, Inc. a good stock to buy?

The fair value guage provides a quick view whether FNCH is over valued or under valued. Whether Finch Therapeutics Group, Inc. is cheap or expensive depends on the assumptions which impact Finch Therapeutics Group, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FNCH.

What is Finch Therapeutics Group, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, FNCH's PE ratio (Price to Earnings) is -0.19 and Price to Sales (PS) ratio is 28.81. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FNCH PE ratio will change depending on the future growth rate expectations of investors.